{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-25-000083","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.963699+00:00","generated_at":"2026-05-18T12:54:00.460515+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aurinia announces positive Phase 1 results for aritinercept; robust Ig reductions support once-monthly dosing","bullets":["Single doses of aritinercept (5-300 mg s.c.) well tolerated in 61 healthy subjects; no treatment-related Grade ≥3 AEs or SAEs.","Mean immunoglobin reductions at Day 28: IgA up to 48%, IgM up to 55%, IgG up to 20%.","Injection site reactions in 24% aritinercept vs 13% placebo; all Grade 1.","Company plans to initiate clinical studies in at least two autoimmune diseases in H2 2025.","Pharmacodynamic effects support once-monthly subcutaneous dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-25-000083","json":"https://secwatch.observer/filing/0001600620-25-000083.json","markdown":"https://secwatch.observer/filing/0001600620-25-000083.md","text":"https://secwatch.observer/filing/0001600620-25-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000083/0001600620-25-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000083/auph-20250630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T12:54:00.460515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}